Delcath Systems (OTCMKTS:DCTH) and Merit Medical Systems (NASDAQ:MMSI) are both medical companies, but which is the better business? We will contrast the two businesses based on the strength of their risk, valuation, earnings, dividends, institutional ownership, profitability and analyst recommendations.
This is a breakdown of current ratings for Delcath Systems and Merit Medical Systems, as reported by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Merit Medical Systems||1||0||8||0||2.78|
Earnings and Valuation
This table compares Delcath Systems and Merit Medical Systems’ top-line revenue, earnings per share and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Delcath Systems||$2.71 million||1.16||-$45.11 million||N/A||N/A|
|Merit Medical Systems||$727.85 million||4.24||$27.52 million||$1.28||43.97|
Merit Medical Systems has higher revenue and earnings than Delcath Systems.
Insider & Institutional Ownership
96.2% of Merit Medical Systems shares are held by institutional investors. 0.0% of Delcath Systems shares are held by company insiders. Comparatively, 5.2% of Merit Medical Systems shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.
Risk and Volatility
Delcath Systems has a beta of 0.38, indicating that its share price is 62% less volatile than the S&P 500. Comparatively, Merit Medical Systems has a beta of 1.22, indicating that its share price is 22% more volatile than the S&P 500.
This table compares Delcath Systems and Merit Medical Systems’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Merit Medical Systems||4.72%||10.86%||6.55%|
Merit Medical Systems beats Delcath Systems on 11 of the 11 factors compared between the two stocks.
About Delcath Systems
Delcath Systems, Inc., an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers. The company is developing melphalan hydrochloride for Injection for use with the Delcath hepatic delivery system to administer high-dose chemotherapy to the liver. It offers melphalan hydrochloride under the Delcath Hepatic CHEMOSAT Delivery System for Melphalan name in Europe. The company was founded in 1988 and is headquartered in New York, New York.
About Merit Medical Systems
Merit Medical Systems, Inc. engages in the manufacture and market of proprietary disposable medical devices. It operates through Cardiovascular and Endoscopy segments. The Cardiovascular segment consists of peripheral intervention, cardiac intervention, interventional oncology and spine, and cardiovascular and critical care product groups. The Endoscopy segment integrates advanced non-vascular stent technology with balloon dilators, inflation devices, guide wires, procedure kits, and other devices that are used by gastroenterologists, endoscopists, pulmonologists, and thoracic and general surgeons. The company was founded by Fred P. Lampropoulos, Darla Gill, Kent W. Stanger and William Padilla in July 1987 and is headquartered in South Jordan, UT.
Receive News & Ratings for Delcath Systems Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Delcath Systems and related companies with MarketBeat.com's FREE daily email newsletter.